| Literature DB >> 29788871 |
Dimitri Poddighe1, Micol Romano2, Maurizio Gattinara2, Valeria Gerloni2.
Abstract
Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate the specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidence regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Biologics; JIA; clinical evidence; immunology; pharmacodynamics; pharmacokinetics.
Mesh：
Substances：
Year: 2018 PMID： 29788871 DOI： 10.2174/0929867325666180522085716
Source DB: PubMed Journal: Curr Med Chem ISSN： 0929-8673 Impact factor: 4.530